# Sedation, analgesia and delirium: study objectives

> **Educational work by a pre-medical student — not medical advice.** Not a clinical protocol, prescription, or patient handout, and not for patient care. See [DISCLAIMER](../DISCLAIMER.md).

Independent premedical study objectives, revised 27 October 2026. No medication regimen or patient-level sedation target is prescribed.

## Distinguish goals

Explain the differences among pain relief, anxiolysis, hypnosis, amnesia, delirium assessment and neuromuscular paralysis. A movement-free patient may still require analgesia and sedation; a monitor value does not independently establish either.

## Compare benefits and harms

For a proposed medicine, identify the specific indication, study population, comparator, desired outcome, hemodynamic effects, respiratory effects and relevant uncertainty. Do not describe dexmedetomidine as hemodynamically neutral or a drug combination as automatically safe. Distinguish approved product labeling, off-label use and evidence of benefit; the repository does not decide regulatory status.

## Evaluate context

- Explain how shock, organ dysfunction, neurologic assessment and ventilation can create competing sedation priorities.
- Compare light-sedation goals with selected contexts that may require a different approach; do not assign one RASS target to every patient.
- Consider pain, hypoxemia, withdrawal, medication effects, sleep and other contributors to agitation or altered attention.
- Use the SCCM 2018 framework together with its 2025 focused update where applicable; see the [source guide](../references/bibliography.md).
- Separate symptom-focused care, active disease treatment and code status. DNI is not synonymous with comfort-only care.

A successful exercise identifies uncertainty and need for qualified team assessment. It does not demonstrate competence to prescribe, administer, monitor or titrate these medicines.